ipsapirone

05/01/1994 - "A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder."
01/01/1993 - "The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial."
12/01/1993 - "A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial."
01/01/1993 - "In this four-week, double-blind, 19-center study, 249 outpatients with generalized anxiety disorder were randomized to one of four treatments: ipsapirone, 5 or 10 mg t.i.d., diazepam 5 mg t.i.d., or placebo. "
01/01/1990 - "In this study, ipsapirone at 15 mg or 30 mg was compared with diazepam at 15 mg and placebo in a double-blind, random assignment study design in patients with generalized anxiety disorder (GAD). "

08/01/1998 - "Ipsapirone, an azapirone with 5-hydroxytryptamine (5-HT1A) partial agonist activity, has been shown in preliminary studies to be effective in the treatment of major depressive disorder. "
07/01/1998 - "Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants."

05/01/2003 - "In conclusion, our results demonstrate that effective treatment of panic disorder has divergent effects on the psychological, neuroendocrine and temperature responses to ipsapirone."
08/01/2002 - "Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder."
05/01/2000 - "The administration of m-CPP or ipsapirone was followed by comparable psychological symptoms and, in 55% of all patients, panic attacks. "
05/01/2000 - "Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder."
01/01/1992 - "To explore 5-HT1A receptor responsivity in panic disorder (PD), hypothermic, neuroendocrine and behavioral responses to the selective partial 5-HT1A receptor agonist ipsapirone (IPS) were investigated in patients with primary PD and healthy controls. "

01/01/1987 - "Ipsapirone partly inhibited in rats but not in mice the 8-OH-DPAT-induced hypothermia. "
10/01/1995 - "Ipsapirone administration produced a significant increase in plasma cortisol levels as well as hypothermia. "
11/01/1994 - "Similarly, administration of various doses of ipsapirone (a 5-HT1A agonist) produced hypothermia that was significantly less in the FH rat strain relative to the Wistar rat strain. "
01/01/1986 - "The data suggest that TVX Q 7821 is a good presynaptic 5-HT1A antagonist in mice, as indicated by the 8-OH-DPAT-induced hypothermia and 5-HT synthesis rate studies. "
05/01/2000 - "In the patient group, there was also a trend towards an increased cortisol response after administration of m-CPP and a decreased cortisol and hypothermia response after administration of ipsapirone compared to the control group. "

02/16/1993 - "In a first series of experiments, ipsapirone administration for 1, 8, 15, and 20 days reduced the duration fo shock-induced ultrasonic vocalization. "
11/01/1991 - "Administration of ipsapirone (10 mg/kg) decreased the number of aggressive attacks of wild and domesticated rats in the test of shock-induced aggression and blocked manifestation of defensive reaction to the experimenter in wild rats. "
06/08/1990 - "The effect of ipsapirone on behavioural and cardiac responses in the shock-probe/defensive burying test in male rats."
05/01/1992 - "A recent study, however, found that buspirone and ipsapirone increased operant responding suppressed by a stimulus which preceded unavoidable shock, suggesting that conditioned emotional response protocols may be more sensitive than punishment procedures. "
02/01/1995 - "Intrahippocampal application of 8-OH-DPAT or ipsapirone produced a dose-dependent inhibition of the firing of serotonergic DRN neurons and of the shock-induced USV response. "